Veradermics is set to raise $200 million in an IPO to fund its novel extended-release oral minoxidil for pattern hair loss.

Cystinosis requires lifelong cystine-depleting therapy; however, currently approved cysteamine products, Cystagon® and Procysbi®, are associated with frequent dosing, gastrointestinal intolerance, and ...

QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

With the expanded indication, Efmody is now indicated for both adrenal insufficiency and congenital adrenal hyperplasia in ...

The Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, an oral formulation of arsenic trioxide, for the treatment of acute promyelocytic leukemia (APL), an aggressive ...

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyUnique sublingual formulation ...

Explore intellectual opportunities and connect with your community for inspiring results.

The hype around educational reforms has abated slightly, but the scandal of the reforms persists. And in saying scandal, I ...

As functional drinks move further into the mainstream, 2026 is signaling a shift in how consumers engage with the category.

Frontage Laboratories, Inc. ("Frontage"), a global Contract Research, Development and Manufacturing Organization (CRDMO), ...

The FDA has cleared Crown Point, Ind.-based OYE Therapeutics’ investigational new drug application for OYE-101, clearing the company to begin clinical development. OYE-101 is an intravenous caffeine ...